• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    2/13/24 5:52:28 PM ET
    $IRAA
    Blank Checks
    Finance
    Get the next $IRAA alert in real time by email
    SC 13G/A 1 IrisAcquisition.txt IRIS ACQUISITION CORP Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No._1)* (Name of Issuer) Iris Acquisition Corp (Formerly known as Tribe Capital Growth Corp I) (Title of Class of Securities) Class A Common Stock, par value $0.0001 per share (CUSIP Number) 89601Y101 (Date of Event Which Requires Filing of this Statement) 12/31/2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 89601Y101 (1) Names of reporting persons Polar Asset Management Partners Inc. (2) Check the appropriate box if a member of a group (see instructions) (a) (b) (3) SEC use only (4) Citizenship or place of organization Ontario, Canada Number of shares beneficially owned by each reporting person with: (5) Sole voting power 0 (6) Shared voting power (7) Sole dispositive power 0 (8) Shared dispositive power (9) Aggregate amount beneficially owned by each reporting person 0 (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions) (11) Percent of class represented by amount in Row (9) 0.0% (12) Type of reporting person (see instructions) IA Item 1(a) Name of issuer: Iris Acquisition Corp (Formerly known as Tribe Capital Growth Corp I) Item 1(b) Address of issuer's principal executive offices: Floor 3 Zephyr House, 122 Mary Street, George Town PO Box 10085 Grand Caymans 2(a) Name of person filing: This statement is filed by Polar Asset Management Partners Inc., a company incorporated under the laws of Ontario, Canada, which serves as the investment advisor to Polar Multi-Strategy Master Fund, a Cayman Islands exempted company ("PMSMF") with respect to the shares directly held by PMSMF. 2(b) Address or principal business office or, if none, residence: 16 York Street, Suite 2900, Toronto, ON, Canada M5J 0E6. 2(c) Citizenship: Canada 2(d) Title of class of securities: Class A Common Stock, par value $0.0001 per share 2(e) CUSIP Number: 89601Y101 Item 3. [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o); [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c); [ ] Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c); [ ] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); [ ] An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); [ ] An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); [ ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); [x] A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); [ ] Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: The Reporting Person is an investment fund manager, portfolio manager, exempt market dealer and commodity trading manager registered with the Ontario Securities Commission. Item 4. Ownership as of December 31, 2023 1. Polar Asset Management Partners Inc. (a) Amount beneficially owned: 0 (b) Percent of class: 0.0% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 0 (iv) Shared power to dispose or to direct the disposition of: 0 Item 5.Ownership of 5 Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ]. Instruction. Dissolution of a group requires a response to this item. Not applicable Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Not applicable Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reporting on by the Parent Holding Company or Control Person. Not applicable Item 8. Identification and Classification of Members of the Group Not applicable Item 9. Notice of Dissolution of Group. Not applicable Item 10. Certifications By signing below I certify that, to the best of his/her knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 13, 2024 POLAR ASSET MANAGEMENT PARTNERS INC. By: /s/ Andrew Ma Name: Andrew Ma Title: Chief Compliance Officer
    Get the next $IRAA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRAA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IRAA
    SEC Filings

    View All

    SEC Form 15-12G filed by Iris Acquisition Corp

    15-12G - Iris Acquisition Corp (0001831874) (Filer)

    4/30/25 9:25:13 AM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form 10-K filed by Iris Acquisition Corp

    10-K - Iris Acquisition Corp (0001831874) (Filer)

    4/15/25 9:48:28 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form NT 10-K filed by Iris Acquisition Corp

    NT 10-K - Iris Acquisition Corp (0001831874) (Filer)

    3/31/25 4:01:42 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Saba Capital Management, L.P. sold $8,781,435 worth of shares (853,395 units at $10.29) (SEC Form 4)

    4 - Iris Acquisition Corp (0001831874) (Issuer)

    9/28/23 10:05:40 AM ET
    $IRAA
    Blank Checks
    Finance

    New insider Moore Capital Management, Lp claimed ownership of 100,000 shares (SEC Form 3)

    3 - Iris Acquisition Corp (0001831874) (Issuer)

    9/26/23 4:43:11 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form 3: New insider Saba Capital Management, L.P. claimed ownership of 853,395 shares

    3 - Iris Acquisition Corp (0001831874) (Issuer)

    2/23/23 1:13:50 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Legion Partners Issues Letter to The Chefs' Warehouse, Inc. Shareholders Calling for Urgently Needed Board Change

    Highlights Company's Chronic Operational and Share Price Underperformance and the Need for New Skill Sets in the Boardroom to Help Chef Reach its Full Potential Nominates Four Highly Qualified, Independent Directors Who Would Bring Valuable Experience in Operations, Finance, Information Systems, Capital Allocation and Strategic Planning to the Board Legion Partners Asset Management, LLC, together with its affiliates (collectively, "we" or "Legion Partners"), is a significant shareholder of The Chefs' Warehouse, Inc. ("Chef", or the "Company") (NASDAQ:CHEF). Today, Legion Partners issued a public letter to the Company's shareholders announcing its nomination of four candidates to the Boa

    2/8/24 8:30:00 AM ET
    $AMPS
    $CHEF
    $F
    Electric Utilities: Central
    Utilities
    Food Distributors
    Consumer Discretionary

    Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

    NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (NASDAQ:IRAA), a publicly traded special purpose acquisition company ("SPAC") formed for the purpose of acquiring or merging with one or more businesses, announced they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be renamed "Liminatus Pharma, Inc.". The combined company's common stock is expected to be listed on the Nasdaq Capital Market. The transaction funding includes commitments for a $15

    12/5/22 7:00:00 AM ET
    $IRAA
    Blank Checks
    Finance

    Liminatus Pharma LLC and Iris Acquisition Corp to combine to incorporate and accelerate much-needed cancer treatments

    Businesses announce Definitive Business Combination Agreement and plan to operate under Liminatus Pharma The transaction values the combined companies at a pro forma enterprise value of $334 million The immune-modulating cancer treatments being developed by Liminatus are a GCC Vaccine, GCC CAR-T therapy and a CD47 immune checkpoint inhibitor. The GCC vaccine and CAR-T patent portfolio originated from Thomas Jefferson University (TJU). The CD47 checkpoint inhibitor originates from a South Korean biotech company InnoBation Bio Co. Ltd. The transaction is expected to be completed in the first half of 2023 Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company develo

    11/30/22 8:46:00 PM ET
    $IRAA
    Blank Checks
    Finance

    $IRAA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    2/14/24 5:28:26 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    2/13/24 5:52:28 PM ET
    $IRAA
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by Iris Acquisition Corp (Amendment)

    SC 13G/A - Iris Acquisition Corp (0001831874) (Subject)

    9/27/23 11:10:24 AM ET
    $IRAA
    Blank Checks
    Finance